We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The review of the safety of isotretinoin has concluded.
New measures strengthen the safe use of the acne drug isotretinoin for patients across the UK, following a patient-focused expert review
Call for information to support a review of isotretinoin, a treatment for severe acne. This review is being undertaken by the Medicines and Healthcare products Regulatory Agency with advice from the Commission on Human Medicines and the Isotretinoin Expert Working...
We are seeking views on a proposal to make Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel available from general sales outlets.
We have strengthened the safe use of isotretinoin through the introduction of additional oversight of the initiation of isotretinoin in patients under 18 years and through improved assessment and monitoring of mental health and sexual function issues. We ask healthcare...
Check the tariff classification for preparations put up for retail sale.
Report of Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
Check what you need to do to sell cosmetic products in Great Britain.
Following an expert safety review of isotretinoin, the Commission on Human Medicines has agreed to a number of recommendations to strengthen the safe use of the treatment.
The MHRA has today announced that 2 Acnecide products will be formally reclassified from pharmacy to general sale list medicines.
Report of the Commission on Human Medicines (CHM) Isotretinoin Expert Working Group and plain-language summary of the recommendations.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
We are reviewing the risks and benefits of the acne medicine, isotretinoin. In particular whether some of the possible psychiatric and sexual side effects continue after treatment has been stopped.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).